You are here : Home > Research entities > Medicines and Healthcare Technologies

Institute | Diagnosis and innovative treatment | Mass spectrometry | Biomarkers


Medicines and Healthcare Technologies

​​ ​​Français​
Published on 20 November 2026
HEAD​ STÉPHANIE SIMONstephanie.simon@cea.fr 
​DEP​​​​​UTY
GABRIEL GRAS​​gabri​​el.gras@cea.fr
​ASSISTANT ​SANDRINE LEBLOIS
​+33 1 69 08 72 99
​​​​ ​​
​​​
Organisation

Located at two CEA sites (Saclay and Marcoule), the Department of Medicines and Technologies for Health (DMTS) - part of the Frédéric ​​Joliot Institute for Life Sciences and directed by Stéphanie Simon - is a joint research unit (Unité Mixte de Recherche) involving the CEA, the University of Paris-Saclay, and INRAe. The DMTS conducts research in the field of molecular innovation for therapeutic and in vitro diagnostic purposes, organized around three core areas​:

  • ​from the des​​​ign of chemical tools f​​​or biology and small bioactive molecules to their functional evaluation​,

  • from molecular enginee​ring of proteins to their therapeutic and diagnostic applications, and,

  • ​from discovery of biomarkers to diagnostic tests.​

These activities draw on unique expertise in organic chemistry (notably bioorthogonal chemistry), analytical chemistry (particularly mass spectrometry), isotopic labeling (both radioactive and non-radioactive) and associated imaging techniques, molecular engineering and immunogenicity of proteins, immunoanalysis, cellular engineering, and preclinical evaluation models. A key defining feature of the department is its translational focus, evidenced by the creation of numerous spin-off companies designed to leverage patents for potential drug candidates, as well as a joint laboratory with an in vitro diagnostics firm, which helps accelerate the market launch of rapid diagnostic tests. Finally, the DMTS is a major contributor to the interministerial R&D program on CBRNE (Chemical, Biological, Radiological, Nuclear, and Explosive) threats - a program entrusted to the CEA - which aims to develop preventive and response measures against such hazards. In this capacity, the department carries out work in the areas of detection, in vitro diagnostics, and the development of medical countermeasures against chemical and biological threat agents. ​​

The department is org​​​anized into three units:

Molecular labeling and bio-inorganic chemistry (SCBM)
Molecular engineering of proteins  (SIMoS)
Pharmacology and immunoanalysis  (SPI)​


LATEST NEWS FROM DMTS

Exceptional facilities and platforms

To carry out their activities, researchers of Medicines and Healthcare Technologies Department have access to several research platforms, two of which certified IBiSA, within the Frédéric Joliot Institute for Life Sciences:

​ High-Throughput screening (certified IBiSA): biological screening platform for high-throughput compound libraries,
​ Métabolome IDF (certified IBiSA): metabolomic platform. This platform is integrated in the National Infrastructure in Biology and Health (INBS)
MetaboHUB: financed by the Programme of Investments for the Future (PIA)
ProdIg: platform for the production of polyclonal and monoclonal antibodies
SMArt-MS: platform dedicated to the absolute quantification of small molecules, drugs, metabolites and biomarkers in biological fluids
L3 Laboratory: level 3 microbiological safety laboratory

Publications